Longchao Liu

About Longchao Liu

Longchao Liu, With an exceptional h-index of 13 and a recent h-index of 13 (since 2020), a distinguished researcher at University of Texas Southwestern Medical Center, specializes in the field of vaccine, tumor microenvironment, cancer immunotherapy, single-cell sequencing.

His recent articles reflect a diverse array of research interests and contributions to the field:

Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells

Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives

IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer

Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity

Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

Abstract P058: Tumor-targeted IL-2 by engineered mesenchymal stem cells reinvigorates CD8+ T cells

602 AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells

Longchao Liu Information

University

Position

Postdoctoral Researcher

Citations(all)

834

Citations(since 2020)

743

Cited By

245

hIndex(all)

13

hIndex(since 2020)

13

i10Index(all)

13

i10Index(since 2020)

13

Email

University Profile Page

Google Scholar

Longchao Liu Skills & Research Interests

vaccine

tumor microenvironment

cancer immunotherapy

single-cell sequencing

Top articles of Longchao Liu

Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells

Signal Transduction and Targeted Therapy

2023/7/12

Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives

2023/2/10

Longchao Liu
Longchao Liu

H-Index: 7

Jiahui Chen
Jiahui Chen

H-Index: 7

IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer

Nature cell biology

2022/12

Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity

JCI insight

2022/9/9

Longchao Liu
Longchao Liu

H-Index: 7

Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity

Nature cancer

2022/4

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

Cell Reports Medicine

2022/3/15

Abstract P058: Tumor-targeted IL-2 by engineered mesenchymal stem cells reinvigorates CD8+ T cells

Cancer Immunology Research

2022/1

602 AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells

2021/11/1

Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells

Nature biomedical engineering

2021/11

The AIM2 and NLRP3 inflammasomes trigger IL-1–mediated antitumor effects during radiation

Science immunology

2021/5/7

Investigation of antigen-specific T-cell receptor clusters in human cancers

Clinical Cancer Research

2020/3/15

Targeting dendritic cells with a PD-L1 based bispecific antibody rejuvenates specific anti-tumor T cells

2020/7/23

Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3–CD8+ T cells

JCI insight

2020/4/4

See List of Professors in Longchao Liu University(University of Texas Southwestern Medical Center)